SEC Form 4 · accession 0001104659-17-021350
NOVELION THERAPEUTICS INC. · NVLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Benjamin Harshbarger
Officer — General Counsel
Period of report
Apr 1, 2017
Accepted (ET)
Apr 4, 2017 · 4:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827809
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1,F2 | Apr 1, 2017 | M | 178 | — | A | 527 | D | |
| Common Shares | Apr 1, 2017 | F | 57 | $10.74 | D | 470 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2,F3 | — | Apr 1, 2017 | M | 178 | D | — | — | Common Shares | 178 | 177 | D |
Explanation of responses
- F1Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016.
- F2Each restricted stock unit represents a contingent right to receive one common share.
- F333.34% of the grant vested on April 1, 2016 and an additional 33.33% of the grant vested on April 1, 2017. Subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer or one of its affiliates, the remainder of the grant will vest on April 1, 2018.